Distinct phosphodiesterase 5A-containing compartments allow selective regulation of cGMP-dependent signalling in human arterial smooth muscle cells

Cell Signal. 2017 Aug;36:204-211. doi: 10.1016/j.cellsig.2017.04.019. Epub 2017 May 12.


Cyclic GMP (cGMP) translates and integrates much of the information encoded by nitric oxide (NO·) and several natriuretic peptides, including the atrial natriuretic peptide (ANP). Previously, we reported that integration of a cGMP-specific cyclic nucleotide phosphodiesterase, namely phosphodiesterase 5A (PDE5A), into a protein kinase G (PKG)- and inositol-1,4,5-trisphosphate receptor (IP3R)-containing endoplasmic reticulum (ER) signalosome allows localized control of PDE5A activity and of PKG-dependent inhibition of IP3-mediated release of ER Ca2+ in human platelets. Herein, we report that PDE5A integrates into an analogous signalosome in human arterial smooth muscle cells (HASMC), wherein it regulates muscarinic agonist-dependent Ca2+ release and is activated selectively by PKG-dependent phosphorylation. In addition, we report that PDE5A also regulates HASMC functions via events independent of PKG, but rather through actions coordinated by competitive cGMP-mediated inhibition of cAMP hydrolysis by the so-called cGMP-inhibited cAMP PDE, namely phosphodiesterase 3A (PDE3A). Indeed, we show that ANP increases both cGMP and cAMP levels in HASMC and promotes phosphorylation of vasodilator-stimulated phospho-protein (VASP) at each the PKG and PKA phospho-acceptor sites. Since selective inhibition of PDE5 decreased DNA synthesis and chemotaxis of HASMC, and that PDE3A knockdown obviated these effects, our findings are consistent with a role for a PDE5A-PDE3A-PKA axis in their regulation. Our findings provide insight into the existence of distinct "pools" of PDE5A in HASMC and support the idea that these discrete compartments regulate distinct cGMP-dependent events. As a corollary, we suggest that it may be possible to target these distinct PDE5A-regulated pools and in so-doing differentially impact selected cGMP-regulated functions in these cells.

Keywords: IP3R; PKG; cAMP; cGMP; “Arterial smooth muscle”.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arteries / cytology*
  • Atrial Natriuretic Factor / pharmacology
  • Cell Compartmentation
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects
  • Cyclic AMP / metabolism
  • Cyclic GMP / metabolism*
  • Cyclic Nucleotide Phosphodiesterases, Type 3 / metabolism
  • Cyclic Nucleotide Phosphodiesterases, Type 5 / metabolism*
  • Enzyme Activation / drug effects
  • Humans
  • Models, Biological
  • Myocytes, Smooth Muscle / drug effects
  • Myocytes, Smooth Muscle / metabolism*
  • Phosphorylation / drug effects
  • Signal Transduction* / drug effects
  • Sildenafil Citrate / pharmacology


  • Atrial Natriuretic Factor
  • Sildenafil Citrate
  • Cyclic AMP
  • Cyclic Nucleotide Phosphodiesterases, Type 3
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • PDE5A protein, human
  • Cyclic GMP

Grant support